Abstract
The MHC class I molecule, HLA-B27 can be expressed as a number of non-conventional forms, in addition to conventional HLA-B27 heterodimers presenting peptide. This has lead to new avenues of research to explain the association of this molecule with SpA. Surprisingly, HLA-B27 transgenic animal models implicated CD4+ T cells, which conventionally interact with MHC class II molecules, not MHC class I molecules, in the pathogenesis of SpA. One hypothesis to explain these finding is that non-conventional forms of HLA-B27, specifically HLA-B27 homodimers, might mimic MHC class II molecules and be recognised by CD4+ T cells. We investigated whether CD4+ T cells from AS patients can interact with HLA-B27, discovering that indeed CD4+ T cells can interact with various forms of HLA-B27. Here we discuss how such interactions between HLA-B27 and CD4+ T cells could occur in vivo and potential contributions of such interactions to the pathogenesis of SpA.
Keywords: HLA-B27, hypothesis, homodimers, T cells
Current Molecular Medicine
Title: The Recognition of Abnormal Forms of HLA-B27 by CD4+ T Cells
Volume: 4 Issue: 1
Author(s): Louise H. Boyle, Jane C. Goodall and J. S. Hill Gaston
Affiliation:
Keywords: HLA-B27, hypothesis, homodimers, T cells
Abstract: The MHC class I molecule, HLA-B27 can be expressed as a number of non-conventional forms, in addition to conventional HLA-B27 heterodimers presenting peptide. This has lead to new avenues of research to explain the association of this molecule with SpA. Surprisingly, HLA-B27 transgenic animal models implicated CD4+ T cells, which conventionally interact with MHC class II molecules, not MHC class I molecules, in the pathogenesis of SpA. One hypothesis to explain these finding is that non-conventional forms of HLA-B27, specifically HLA-B27 homodimers, might mimic MHC class II molecules and be recognised by CD4+ T cells. We investigated whether CD4+ T cells from AS patients can interact with HLA-B27, discovering that indeed CD4+ T cells can interact with various forms of HLA-B27. Here we discuss how such interactions between HLA-B27 and CD4+ T cells could occur in vivo and potential contributions of such interactions to the pathogenesis of SpA.
Export Options
About this article
Cite this article as:
Boyle H. Louise, Goodall C. Jane and Gaston S. Hill J., The Recognition of Abnormal Forms of HLA-B27 by CD4+ T Cells, Current Molecular Medicine 2004; 4 (1) . https://dx.doi.org/10.2174/1566524043479257
DOI https://dx.doi.org/10.2174/1566524043479257 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stem Cells and Cell Therapy for Bone Repair
Current Molecular Pharmacology Neuroinflammation in Prion Diseases: Concepts and Targets for Therapeutic Intervention
CNS & Neurological Disorders - Drug Targets Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Biomarkers for Predicting the Immunomodulatory Properties of Probiotics
Recent Patents on Biomarkers Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options
Current Drug Targets Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology NADPH Oxidase and Neurodegeneration
Current Neuropharmacology Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir
Current Diabetes Reviews TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Advances in the Knowledge and Clinical Applications of Lactic Acid Bacteria as Probiotics in the Urogenital Tract
Current Women`s Health Reviews Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Transdermal Lipid Nanocarriers: A Potential Delivery System for Lornoxicam
Pharmaceutical Nanotechnology Mucosal HIV Vaccines: Where are We Now?
Current HIV Research Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance
Current Medicinal Chemistry